Lilly/Isis Affinitak development dropped
Executive Summary
Isis "will not invest further in the development of Affinitak," firm says following failure of second pivotal non-small cell lung cancer trial conducted by partner Lilly. Study investigated the antisense inhibitor in combination with Lilly's Gemzar (gemcitabine) and cisplatin; trial results were to determine fate of drug after failure of first Phase III trial in combination with paclitaxel and carboplatin (1"The Pink Sheet" March 24, 2003, p. 29)...
You may also be interested in...
Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study
Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.